Trial Profile
Phase II Study of ENMD-2076 in Chinese Patients With Ovarian Clear Cell Carcinomas
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2015
Price :
$35
*
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 17 Apr 2015 New trial record
- 30 Mar 2015 According to CASI Pharmaceuticals media release,China Food and Drug Administration (CFDA) has approved the application to conduct a Phase 2 clinical trial in ovarian clear cell carcinoma patients.